Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartstagecardiacventricularartery
  Phrases that lowered it: volunteerscrossoverdrugsdrugalcohol
• Primary purpose: not given (lowers risk) · Design
• Sponsor's past termination rate: 14.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 160 (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Maximum age: 90 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 421 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 0 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• CD-NP in Subjects With Stable Chronic Heart Failure NCT00620308 · started 2008 · scored riskier than 60% of active trials completed
• Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure NCT00839007 · started 2009 · scored riskier than 32% of active trials completed
• Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF) NCT00699712 · started 2008 · scored riskier than 72% of active trials completed
• Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction NCT00818701 · started 2009 · scored riskier than 74% of active trials terminated
• REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction NCT06237309 · started 2024 · scored riskier than 89% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.